2025-04-11 - Analysis Report
## Recursion Pharmaceuticals Inc. (RXRX) Stock Review

**0. Key Figures Summary:**

RXRX is significantly underperforming the S&P 500, exhibiting a substantial negative return compared to the benchmark.  Technical indicators suggest a potentially oversold condition, but fundamental analysis reveals ongoing financial challenges.

**1. Performance Comparison & Alpha/Beta Analysis:**

Recursion Pharmaceuticals Inc. (RXRX) is a clinical-stage biopharmaceutical company leveraging AI to discover and develop new medicines.

* **Cumulative Return (RXRX):** -51.54%
* **Cumulative Return (VOO):** 8.78%
* **Return Difference:** -60.3% (This means RXRX underperformed VOO by 60.3 percentage points.)
* **Relative Divergence Rank:** 10.5% (This places the current underperformance at the 10.5th percentile of historical divergence between RXRX and VOO).

The provided Alpha/Beta analysis shows consistently negative alpha values across the periods, indicating underperformance relative to the market (Beta > 1 signifies higher volatility than the market).  The high Maximum Drawdown (MDD) further highlights the significant risk associated with this investment.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2021-2023  | 5.0% | 73.6% | -10.0% | 3.7   |
| 2022-2024  | 0.0% | 73.6% | -21.0% | 2.5   |
| 2023-2025  | 0.0% | 73.6% | -8.0% | 1.8   |


**2. Recent Price Movement:**

* **Closing Price:** $4.65
* **Last Market Price:** $4.38 (-5.81% change from previous close)
* **5-Day Moving Average:** $4.37
* **20-Day Moving Average:** $5.70
* **60-Day Moving Average:** $6.97

The stock price is currently trading below all three moving averages, indicating a downtrend. The recent -5.81% drop signifies a notable negative price movement.


**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.4271 (Medium Risk)
* **RSI:** 28.21 (Oversold territory; often signals potential bounce, but not guaranteed)
* **PPO:** -2.76 (Negative PPO indicates bearish momentum)
* **20-Day Relative Divergence Change:** +6.4% (Short-term upward movement, but context within the larger downtrend is crucial)
* **Expected Return:** -299.9% (This extremely negative expected return suggests significant further downside risk in the short to medium term).  This metric needs careful scrutiny given the negative overall performance and significant market volatility.

**4. Recent Earnings Analysis:**

The company consistently reports negative EPS and relatively low revenue, indicating substantial financial challenges.

| Date       | EPS    | Revenue     |
|------------|--------|-------------|
| 2024-11-06 | -$0.34 | $0.03B      |
| 2024-08-08 | -$0.40 | $0.01B      |
| 2024-05-09 | -$0.39 | $0.01B      |
| 2023-11-09 | -$0.43 | $0.01B      |
| 2024-11-06 | -$0.43 | $0.01B      |


**5. Financial Information:**

Both Revenue and Profitability, and Capital and Profitability tables show significant inconsistencies and negative figures, pointing to significant financial weakness.  The highly variable profit margins and negative ROE across quarters are extremely concerning.


| Quarter     | Revenue | Profit Margin |
|-------------|----------|---------------|
| 2024-12-31 | $0.00B  | -183.62%      |
| 2024-09-30 | $0.03B  | 53.69%       |
| 2024-06-30 | $0.01B  | 36.14%       |
| 2024-03-31 | $0.01B  | 17.23%       |
| 2023-12-31 | $0.01B  | 6.99%        |


| Quarter     | Equity  | ROE       |
|-------------|---------|-----------|
| 2024-12-31 | $1.03B  | -17.29%   |
| 2024-09-30 | $0.52B  | -18.27%   |
| 2024-06-30 | $0.58B  | -16.69%   |
| 2024-03-31 | $0.40B  | -22.78%   |
| 2023-12-31 | $0.46B  | -20.07%   |



**6. Overall Analysis:**

RXRX is currently experiencing significant financial difficulties, reflected in negative EPS, low revenue, highly volatile and negative profit margins, and negative ROE. While some technical indicators suggest potential oversold conditions, the fundamental weakness significantly outweighs any short-term technical signals.  The extremely negative expected return underscores the high risk involved.  A long-term (2+ years) investment strategy for RXRX should be approached with extreme caution and only after thoroughly evaluating the company's long-term prospects for turning its financial performance around. The significant underperformance against the S&P 500 further supports a negative outlook.  Any investment should be viewed as highly speculative and potentially resulting in substantial losses.
